HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $195 to $200.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $195 to $200.